Targeting Interleukin-4 Receptor Alpha by Hybrid Peptide for Novel Biliary Tract Cancer Therapy
Figure 2
Cytotoxic activity of IL-4Rα-lytic hybrid peptide. Six BTC cell lines were cultured with various concentrations of IL-4Rα-lytic hybrid peptide or lytic peptide (0–20 μM) for 72 h, and cytotoxic activity was assessed using WST-8 reagent. The results are represented as mean ± SD (bars) of triplicate determinations, and the assay was repeated three times.
